Heidelberg Pharma AG is moving closer to signing off its transformative link-up with China's Huadong Medicine Co., Ltd. and with the continuing support of long-time backer Dievini, the German group believes it is well equipped to achieve its aim of becoming a global player in the antibody-drug conjugate (ADC) space.
Earlier this month, Heidelberg, which is developing the toxin amanitin into cancer therapies, noted that the various closing conditions regarding an equity investment by Huadong to be made in August (and announced in February) have been met